Over the past years, studies have described that users of antipsychotics are less likely to develop cancer than the population in general due to cytotoxic properties of this 
| INTRODUC TI ON
Cancer may be considered the major cause of morbidity and mortality in the world, affecting all countries and regions. This disease was responsible for 8 millions of deaths in 2012 with a mortality rate of 102 per 100 000. Africa, Asia, and Central and South America respond for more than 60% of the world's cancer cases and 70% of the cancer deaths. 1 Chemotherapy is the consolidated treatment for a variety of cancers. Nevertheless, although chemotherapy eliminates most of the neoplastic cells, cancer stem cells (CSC) may survive and promote tumour recurrence, an important characteristic determined as chemoresistance. 2 There is an urgent need to develop alternative therapies able to overcome chemoresistance in cancers.
Interestingly, reduced incidence of cancer in patients with schizophrenia has been reported, 3 and the carcinogenesis process in these patients has been unrelated to cancer risk factor exposure. 4 Although the cause of this apparent reduction in cancer incidence remains unclear, antipsychotic drugs are suggested as the possible mediators of this effect. 3 Dricoll et al 5 and demonstrated that psychotropic agents were 18 times more likely to possess some form of antiproliferative potential when compared with a random population of molecules. Subsequently, many studies using cancerous cell lines confirmed that antipsychotic drugs show cytotoxic potential. 6 Pimozide, an orally active antipsychotic agent used to treat Tourette's syndrome, chronic psychosis, resistant phonic, and motor tics, 7 has been widely indicated as a potential anticancer agent. All studies that used Pimozide as an anti-tumour drug showed positive results, mainly against CSC, which are responsible for chemoresistance. 33, 35 However, the antipsychotic cytotoxicity is not primarily related to the ligand-based actions on dopaminergic and serotonergic receptors, because drug concentrations many times greater than those required to saturate these receptor types are necessary to induce cytotoxicity. 14 An alternative explanation for cytotoxicity of Pimozide is the direct interaction with three vias: STAT3 and STAT5, wnt/β-catenin, and USP1/WDR48. Based on the potential antineoplastic and incompletely study of its pharmacological properties, the aim of this manuscript was to review the role of the Pimozide during the tumorigenesis process and its potential in revert the process of undifferentiation and proliferation of CSC through these different vias.
| C AN CER S TEM CELL S
The existence of hematopoietic stem cells in human cord blood was first described by Prindull, Prindull and Muellen. 36 Later, the World Health Organization defined stem cells as cells that can divide to generate a more specific cell or another identical stem cell. 37 Currently, these cells are classified into three groups: totipotent (ability to generate an entire organism), pluripotent (ability to develop into all cell types of the embryo proper), and multipotent (able to generate most of the tissues of an organism). Therefore, stem cells also may be divided according to the developmental stage from which they were obtained, as adult or embryonic. 38, 39 The most important stem cell property is self-renewal. However, this characteristic may be related to the malignancy process. This drug acts on neurons in the CNS by blocking dopaminergic, serotonergic and other central nervous receptors which are not completely known. 7 Pimozide demonstrates little (<10-fold) or no selectivity for D2 or 5-HT2A receptors due to their HERG channel affinities. 45 This lack of selectivity underlies a series of secondary alterations in central dopamine metabolism and function; which causes both therapeuticity against the symptoms of schizophrenia, psychosis, and resistant phonic tics, as undesirable effects 7 (significant QT interval prolongation). 45 Kongsamut et al 45 determined that dose-response effect of Pimozide can be obtained through IC 50 value of 18 nmol/L, using a dosage of 14-22 nmol/L (95% confidence limits). Additionally, according to the DrugBank, the oral LD50 is 1100 mg/kg in rat, 228 mg/kg in mouse, but the precise lethal dose in humans is unknown. 46 Though a very much lower dosage (12 mg) caused regression of metastatic melanoma, which will be described in this study. 8 Additionally, Pimozide has showed an anticancer effect on other types of cancer: melanoma, CNS tumours, osteosarcoma, neuroblastoma, myeloproliferative neoplasms, breast, lung, prostate, ovarian, colorectal, pancreatic and hepatocellular carcinoma. Although, patients with mental disorders such as schizophrenia are less likely to develop cancer than the general population, 47 there are yet no reports about the cancer incidence specifically in Pimozide users.
F I G U R E 1 Structural formula of Pimozide

| PIMOZIDE A S A P OTENTIAL ANTI C AN CER AG ENT
| Melanoma
The first description of using Pimozide as an anticancer drug was given by Taub and Baker. 8 
| Lung Carcinoma
Reinforcing 
| Ovarian carcinoma
Lazo et al (1986) studied the effect of Bleomycin and Pimozide on human ovarian carcinoma cells (SK-OV) using a clonogenic assay.
One-hour exposure to the combination of both drugs in non-
Pimozide also enhanced the toxicity of Bleomycin to human granulocyte/macrophage and erythroid stem cell colonies. 
| Myeloproliferative neoplasms
| Hepatocellular carcinoma
In addition, a possible relation between this drug and stem-like cell maintenance has been studied. Chen et al, 33 in vitro, investi- 
| MECHANIS M OF AC TI ON OF PIMOZIDE IN C AN CER
The real antineoplastic action mechanism of Pimozide remains unclear. However, three probable vias can justify the positive results reported: STAT3 and STAT5, wnt/β-catenin, and USP1/WDR48.
| STAT3 and STAT5
Signal transducer and activator of transcription (STAT) is a transcription factor often activated in cancer. 51 Receptor and non-receptor tyrosine kinases are responsible for activating STATs located in the plasma membrane via phosphorylation of a tyrosine residue. STAT activation induces dimerization via reciprocal phosphotyrosine-SH2 interaction between two STAT molecules. After that, the STAT dimers are translocated to the nucleus where they activate the transcription of their target genes. These genes code proteins required for self-renewal, cell survival and proliferation (Figure 2 Regarding STAT5 specifically, the authors Nogami et al 31 and
Bar-Natan et al 29 In summary, this via has been so widely studied that research groups have synthesized derivatives of this drug with cytotoxic activity able to decrease the levels of phosphorylated STAT5, a specific compound with important structure modifications which leads this drug to be even more active than conventional Pimozide. 
| wnt/β-catenin
This is a pathway less known since there are only two studies exploring this mechanism of action of Pimozide. The Wnt/β-catenin signalling pathway has been reported for leading to EMT in many cancers.
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| USP1/WDR48
The most studied mechanism of action of Pimozide is related to the USP1/WDR48 complex. The process of cancer progression inhibition by means of this via occurs following these steps:
| First step: Regulation of the development and differentiation by bHLH transcription factors
bHLH is the third greatest family of transcription factors present in the human genome. 58 These transcription factors have been described as significant regulators of development. 59 The deregulated growing during tumourigenesis is associated with many pathways related to the helix-loop-helix (HLH) gene. 60 The class I of bHLH homodimers promotes the activation of anti-proliferative genes, as cyclin-dependent kinase inhibitor (CDKN1A, CDKN2A and CDKN2B). 61 The class II of bHLH proteins composes heterodimers with the class I, which regulates tissue-specific genes. Besides, bHLH also contributes to perpetuation of the cell line. 
| Second step: ID proteins act as a dominant negative of bHLH by forming heterodimers
ID protein is responsible for inhibiting the HLH transcription factor from binding to DNA. 63 It is possible by composition of high-affinity heterodimers that prevent this binding and, consequently, the transcription of differentiation-associated genes. In summary, IDs are able to inhibit differentiation of certain lineages and stimulate its proliferation potential. 63, 64 A range of tumours has presented evidence of ID dysregulation;
indeed, ID expression was related with invasiveness, aggressiveness and less differentiated tumour phenotype. 65 Furthermore, a significant connection between ID and metastatic potential in primary tumour with nodal involvement has been reported in the literature. ID1 expression can indicate metastatic behaviour and malignant progression. 66 The greatest ID expression has been associated to poorly differentiated tumours, higher odds to metastasis and poor prognosis. 
| CON CLUS ION
R E FE R E N C E S
